23:51 , Feb 21, 2019 |  BC Week In Review  |  Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed. HaiHe...
21:30 , Feb 19, 2019 |  BC Extra  |  Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed. HaiHe...
21:17 , Feb 11, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain In vitro and rat studies identified a benzimidazole-based PTGER4 antagonist that could help treat pain. High throughput screening of Bayer AG's compound library, in vitro enzymatic activity assays and optimization of hits yielded...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
13:29 , Dec 5, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived placenta-like organoids could be used to study preeclampsia and other pregnancy-related disorders and screen therapies to treat them. The organoids are generated by culturing human placenta-derived trophoblasts in culture media with...
23:58 , Nov 28, 2018 |  BC Extra  |  Preclinical News

Placental organoid could improve preeclampsia therapies

A placenta-like organoid developed by a University of Cambridge team could improve understanding of maternal-fetal first-trimester disorders like preeclampsia and provide a model to study therapies to treat first-trimester complications. Challenges in preeclampsia and other...
22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
17:55 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection Mouse studies suggest antagonizing PTGER4 could help treat infectious colitis. In a mouse model of Citrobacter rodentium -induced colitis, a PTGER4 antagonist tool compound decreased weight loss, numbers of infectious bacteria in...
15:53 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Gastrointestinal Cell culture and mouse studies suggest deoxycholate-mediated PGE2 inhibition or agonism of FXR could help treat colonic injury. In a mouse model of colonic mucosal biopsy injury, PGE2 levels were higher during the...
18:09 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Adlai Nortye raises $50M series B

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) raised over $50 million in a series B round led by YuanMing Capital. Matrix Partners China, DT Capital Partners and Yahui Precision Medicine Fund also...